Study ID/ Name

Treatment

N

2‐years survival

1‐year remission

1‐year no edema

1‐year normal VEGF

Adverse event

Kuwabara 1997

Corticosteroid

6

2 (33%)

3 (50%)

3 (50%)

‐

‐

Melphalan

6

6 (100%)

4 (67%)

6 (100%)

‐

2 leukocytopenia

Jaccard 2002

Transplantation

5

4/4 (100%)

5 (100%)

5 (100%)

2/2 (100%)

‐

Dispenzieri 2003

Radiation

64

90%

‐

‐

‐

‐

Melphalan

48

78%

‐

‐

‐

‐

Dispenzieri 2004

Transplantation

16

15 (94%)

14 (87%)

11/14 (79%)

‐

1 transplant‐related death, 5 respiratory failure

Kuwabara 2006

Melphalan

8

8 (100%)

4 (50%)

4/8 (50%)

2/8 (25%)

2 leukocytopenia

Transplantation

4

4 (100%)

4 (100%)

4 (100%)

4 (100%)

‐

Dispenzieri 2008

Transplantation

30*

29 (97%)

‐

‐

‐

15 engraftment syndrome

Kuwabara 2008a

Transplantation

9**

6/6 (100%)

9 (100%)

9 (100%)

9 (100%)

1 respiratory failure

Kuwabara 2008b

Thalidomide

9

3/3 (100%)

5 (56%)

7 (78%)

5 (56%)

3 skin eruption

* Includes 11 of 16 patients in Dispenzieri 2004.

** Includes 4 patients in Kuwabara 2006.